.

Exelixis reported $405.95M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 131.9M 19.38M
Agios Pharmaceuticals AGIO:US $ 5.15M 4.65M
Amgen AMGN:US $ 5084M 407M
AstraZeneca AZN:LN 728.3B 34.55B
Bayer BAYN:GR 7.14B 2.32B
Biomarin Pharmaceutical BMRN:US $ 410.67M 8.28M
Bluebird Bio BLUE:US $ -226000 6.14M
Bristol Myers Squibb BMY:US $ 9210M 33M
Eisai 4523:JP Y 136858M 3305M
Eli Lilly And LLY:US $ 5057.5M 680.4M
Esperion Therapeutics ESPR:US $ 9.66M 2.05M
Exelixis EXEL:US $ 405.95M 63.17M
Glaxosmithkline GSK:US $ 4793M 1342M
IONIS PHARMACEUT IONS:US $ 129.05M 8.7M
MacroGenics MGNX:US 23.6M 12.55M
Merk MRK:US $ 10895M 328M
Moderna Inc MRNA:US 3.37B 1.68B
Nektar Therapeutics NKTR:US $ 16.47M 3.04M
Neurocrine Biosciences NBIX:US $ 373.4M 67.4M
Novartis NOVN:VX 9.34B 277M
Pfizer PFE:US $ 19071M 3420M
Puma Biotechnology PBYI:US $ 44.6M 9.71M
Seattle Genetics SGEN:US $ 391.4M 52.57M
Takeda 4502:JP Y 679583M 114674M
Ultragenyx Pharmaceutical RARE:US $ 81.07M 7.24M
YTE INCY:US $ 866.16M 170.14M